Pfizer Valuation
| PFE Stock | 24.48 0.07 0.29% |
At this time, the company appears to be fairly valued. Pfizer Inc holds a recent Real Value of USD24.94 per share. The prevailing price of the company is USD24.48. Our model determines the value of Pfizer Inc from analyzing the company fundamentals such as Shares Outstanding of 5.62 B, operating margin of 0.39 %, and Return On Equity of 0.36 as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Pfizer's price fluctuation is very steady at this time. Calculation of the real value of Pfizer Inc is based on 3 months time horizon. Increasing Pfizer's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Pfizer's intrinsic value may or may not be the same as its current market price of 24.48, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 24.48 | Real 24.94 | Hype 24.48 | Naive 25.56 |
The intrinsic value of Pfizer's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pfizer's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pfizer Inc helps investors to forecast how Pfizer stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pfizer more accurately as focusing exclusively on Pfizer's fundamentals will not take into account other important factors: Pfizer Total Value Analysis
Pfizer Inc is at this time forecasted to have takeover price of 289.72 B with market capitalization of 214.54 B, debt of 36.2 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Pfizer fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
289.72 B | 214.54 B | 36.2 B |
Pfizer Investor Information
About 71.0% of the company shares are owned by institutional investors. The book value of Pfizer was at this time reported as 17.03. The company has Price/Earnings To Growth (PEG) ratio of 1.19. Pfizer Inc recorded earning per share (EPS) of 5.08. The entity last dividend was issued on the 26th of January 2023. The firm had 100150:333 split on the 1st of July 1999. Based on the analysis of Pfizer's profitability, liquidity, and operating efficiency, Pfizer Inc is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Pfizer Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pfizer has an asset utilization ratio of 55.29 percent. This implies that the Company is making USD0.55 for each dollar of assets. An increasing asset utilization means that Pfizer Inc is more efficient with each dollar of assets it utilizes for everyday operations.Pfizer Ownership Allocation
Pfizer owns a total of 5.62 Billion outstanding shares. The majority of Pfizer Inc outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pfizer Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pfizer. Please pay attention to any change in the institutional holdings of Pfizer Inc as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Pfizer Profitability Analysis
The company reported the revenue of 100.33 B. Net Income was 31.37 B with profit before overhead, payroll, taxes, and interest of 66.23 B.About Pfizer Valuation
The stock valuation mechanism determines Pfizer's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Pfizer Inc based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pfizer. We calculate exposure to Pfizer's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pfizer's related companies.8 Steps to conduct Pfizer's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Pfizer's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Pfizer's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Pfizer's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Pfizer's revenue streams: Identify Pfizer's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Pfizer's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Pfizer's growth potential: Evaluate Pfizer's management, business model, and growth potential.
- Determine Pfizer's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Pfizer's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Pfizer Stock Analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.